Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells $477,451.74 in Stock

Key Points

• Kiniksa Pharmaceuticals COO Eben Tessari sold 13,389 shares worth approximately $477,451.74 on September 5, decreasing his ownership by 23.15%.
• The stock price of Kiniksa Pharmaceuticals reached $36.57 recently, with a market cap of $2.71 billion and a P/E ratio of 914.48.
• Several analysts have expressed positive sentiment, with Jefferies Financial Group raising their target price for Kiniksa from $45.00 to $54.00 and maintaining a "buy" rating.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 13,389 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $35.66, for a total value of $477,451.74. Following the completion of the transaction, the chief operating officer directly owned 44,452 shares of the company's stock, valued at approximately $1,585,158.32. This represents a 23.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Eben Tessari also recently made the following trade(s):

• On Thursday, September 4th, Eben Tessari sold 85,271 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.52, for a total value of $3,028,825.92.
• On Wednesday, September 3rd, Eben Tessari sold 15,091 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.50, for a total value of $535,730.50.
• On Monday, August 18th, Eben Tessari sold 16,200 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $33.77, for a total value of $547,074.00.
• On Tuesday, August 5th, Eben Tessari sold 138,614 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $33.20, for a total value of $4,601,984.80.
• On Monday, July 14th, Eben Tessari sold 18,900 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $28.72, for a total value of $542,808.00.
• On Monday, June 16th, Eben Tessari sold 17,300 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $28.28, for a total value of $489,244.00.
• On Wednesday, June 11th, Eben Tessari sold 45,042 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $30.51, for a total value of $1,374,231.42.
• On Tuesday, June 10th, Eben Tessari sold 15,506 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $30.46, for a total value of $472,312.76.

Kiniksa Pharmaceuticals International Price Performance

Shares of Kiniksa Pharmaceuticals International stock traded up $0.86 on Monday, reaching $36.57. 549,450 shares of the company were exchanged, compared to its average volume of 671,153. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $36.74. The company has a market cap of $2.71 billion, a P/E ratio of 914.48 and a beta of 0.20. The stock's 50 day moving average price is $30.95 and its 200-day moving average price is $26.59.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million during the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, research analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several large investors have recently modified their holdings of KNSA. Rubric Capital Management LP grew its holdings in Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company's stock worth $108,184,000 after acquiring an additional 526,567 shares during the period. Vanguard Group Inc. grew its holdings in Kiniksa Pharmaceuticals International by 4.7% during the first quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company's stock worth $74,606,000 after acquiring an additional 151,604 shares during the period. Acadian Asset Management LLC grew its holdings in Kiniksa Pharmaceuticals International by 22.6% during the second quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company's stock worth $35,067,000 after acquiring an additional 233,668 shares during the period. Qube Research & Technologies Ltd grew its holdings in Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company's stock worth $24,581,000 after acquiring an additional 653,236 shares during the period. Finally, Millennium Management LLC grew its holdings in Kiniksa Pharmaceuticals International by 8.7% during the first quarter. Millennium Management LLC now owns 847,124 shares of the company's stock worth $18,815,000 after acquiring an additional 67,452 shares during the period. Hedge funds and other institutional investors own 53.95% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Jefferies Financial Group boosted their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Sunday. Wedbush reiterated an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Finally, Wells Fargo & Company boosted their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, July 9th. Six analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $41.17.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.